Larvol Delta - MaxCyte-Announces-Strategic-Platform-Licensing-Agreement-with-Anocca-AB-to-Advance-TCRT-Cell-Therapy-Pipeline

Undisclosed KRAS TCR-modified T-cell therapy - Anocca

https://www.globenewswire.com/news-release/2025/07/31/3124964/0/en/MaxCyte-Announces-Strategic-Platform-Licensing-Agreement-with-Anocca-AB-to-Advance-TCR-T-Cell-Therapy-Pipeline.html

Jul 31, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next